Is DEEP VEIN THROMBOSIS a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed DEEP VEIN THROMBOSIS.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 67 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported DEEP VEIN THROMBOSIS to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and DEEP VEIN THROMBOSIS. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause DEEP VEIN THROMBOSIS, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes DEEP VEIN THROMBOSIS. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if DEEP VEIN THROMBOSIS ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing DEEP VEIN THROMBOSIS: 67
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where DEEP VEIN THROMBOSIS is a reported side effect: 2.0126%

FDA reports of any drug causing DEEP VEIN THROMBOSIS : 36294
Average percentage for all medicated patients where DEEP VEIN THROMBOSIS is reported as a complication: 0.2275%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
ANGINA PECTORIS ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with DEEP VEIN THROMBOSIS:

YAZ (8465 patients)
YASMIN (8423 patients)
VIOXX (3670 patients)
ASPIRIN (2470 patients)
FOSAMAX (2419 patients)
DROSPIRENONE AND ETHINYL ESTRADIOL (2146 patients)
HEPARIN SODIUM INJECTION (2115 patients)
NUVARING (2114 patients)
COUMADIN (2013 patients)
PREDNISONE (1877 patients)
IBUPROFEN (1556 patients)
ZOMETA (1513 patients)
ORTHO EVRA (1484 patients)
DEXAMETHASONE (1361 patients)
LASIX (1284 patients)
REVLIMID (1208 patients)
CELEBREX (1159 patients)
SYNTHROID (1159 patients)
LOVENOX (1131 patients)
WARFARIN SODIUM (1121 patients)
LISINOPRIL (1077 patients)
ACETAMINOPHEN (1047 patients)
NEXIUM (995 patients)
ALBUTEROL (983 patients)
PROTONIX (971 patients)
PRILOSEC (971 patients)
AREDIA (969 patients)
DECADRON (944 patients)
AMBIEN (919 patients)
LIPITOR (903 patients)
VICODIN (861 patients)
NEURONTIN (827 patients)
ZOLOFT (823 patients)
OMEPRAZOLE (820 patients)
PREMARIN (788 patients)
FOLIC ACID (768 patients)
LEXAPRO (762 patients)
XANAX (759 patients)
PERCOCET (757 patients)
LEVAQUIN (752 patients)
METHOTREXATE (742 patients)
POTASSIUM CHLORIDE (716 patients)
ATIVAN (712 patients)
ATENOLOL (695 patients)
FUROSEMIDE (692 patients)
HYDROCHLOROTHIAZIDE (679 patients)
CARBOPLATIN (675 patients)
PREDNISONE TAB (665 patients)
PREVACID (651 patients)
LORTAB (651 patients)
MOTRIN (645 patients)
REMICADE (645 patients)
PREMPRO (642 patients)
CISPLATIN (636 patients)
ZOFRAN (635 patients)
LORAZEPAM (628 patients)
HEPARIN (627 patients)
OXYCONTIN (620 patients)
OXYCODONE HCL (615 patients)
LEVOTHYROXINE SODIUM (610 patients)
THALOMID (605 patients)
OCELLA (581 patients)
MULTI-VITAMIN (578 patients)
PRADAXA (567 patients)
SIMVASTATIN (567 patients)
NORVASC (565 patients)
PREDNISOLONE (553 patients)
MULTI-VITAMINS (553 patients)
ASCORBIC ACID (550 patients)
ZYRTEC (549 patients)
ZOCOR (546 patients)
MORPHINE (543 patients)
PLAVIX (536 patients)
FLUOROURACIL (531 patients)
AMOXICILLIN (519 patients)
AVONEX (518 patients)
NAPROXEN (504 patients)
VITAMIN D (502 patients)
XARELTO (498 patients)
ALLOPURINOL (495 patients)
SINGULAIR (494 patients)
ADVAIR DISKUS 100/50 (493 patients)
METFORMIN HCL (489 patients)
FLEXERIL (485 patients)
ZITHROMAX (477 patients)
CYCLOPHOSPHAMIDE (473 patients)
TOPROL-XL (470 patients)
AVASTIN (465 patients)
HUMIRA (463 patients)
COLACE (458 patients)
PAXIL (457 patients)
REGLAN (452 patients)
CALCIUM (449 patients)
ALLEGRA (449 patients)
SEROQUEL (448 patients)
CIPROFLOXACIN (447 patients)
PROVERA (445 patients)
DURAGESIC-100 (444 patients)
DILAUDID (441 patients)
COMPAZINE (435 patients)
VELCADE (431 patients)
DIGOXIN (424 patients)
THALIDOMIDE (424 patients)
GABAPENTIN (419 patients)
NPLATE (417 patients)
PROZAC (415 patients)
FLUCONAZOLE (413 patients)
CYMBALTA (412 patients)
METOPROLOL TARTRATE (409 patients)
EFFEXOR (406 patients)
VINCRISTINE (405 patients)
TRAMADOL HCL (405 patients)
ALPRAZOLAM (404 patients)
ARANESP (396 patients)
CELEXA (391 patients)
TOPAMAX (391 patients)
ZANTAC (390 patients)
WELLBUTRIN (386 patients)
AZITHROMYCIN (385 patients)
BENADRYL (379 patients)
ZYPREXA (373 patients)
CLONAZEPAM (367 patients)
ACCUTANE (367 patients)
DIOVAN (364 patients)
CEPHALEXIN (356 patients)
NSAID'S (354 patients)
PEPCID (353 patients)
ACYCLOVIR (353 patients)
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (353 patients)
DIFLUCAN (352 patients)
LYRICA (351 patients)
TAXOL (350 patients)
INSULIN (348 patients)
MORPHINE SULFATE (347 patients)
CLINDAMYCIN (344 patients)
XELODA (342 patients)
BEXTRA (341 patients)
FENTANYL (340 patients)
BEVACIZUMAB (340 patients)
METRONIDAZOLE (339 patients)
HEPARIN SODIUM (331 patients)
TYLENOL (329 patients)
BACTRIM (329 patients)
TAXOTERE (323 patients)
ONDANSETRON (320 patients)
FLONASE (319 patients)
PROCRIT (318 patients)
TRAZODONE HCL (314 patients)
CLARITIN (310 patients)
FERROUS SULFATE TAB (307 patients)
NITROGLYCERIN (305 patients)
ENOXAPARIN SODIUM (303 patients)
METHYLPREDNISOLONE (303 patients)
TYSABRI (297 patients)
METOCLOPRAMIDE (296 patients)
PROMETHAZINE (296 patients)
CRESTOR (295 patients)
SPIRONOLACTONE (295 patients)
PACLITAXEL (292 patients)
LANTUS (291 patients)
CALCIUM CARBONATE (290 patients)
ALENDRONATE SODIUM (289 patients)
ULTRAM (287 patients)
ANTIBIOTICS (287 patients)
MEGACE (287 patients)
KLONOPIN (287 patients)
VITAMIN B-12 (284 patients)
FORTEO (283 patients)
GLUCOPHAGE (280 patients)
NEUPOGEN (280 patients)
PANTOPRAZOLE (279 patients)
AMLODIPINE (278 patients)
ARIXTRA (273 patients)
ENBREL (273 patients)
PHENERGAN (273 patients)
VANCOMYCIN (272 patients)
FLAGYL (272 patients)
METOPROLOL (271 patients)
KEPPRA (271 patients)
LOPRESSOR (270 patients)
EVISTA (270 patients)
RISPERDAL (267 patients)
WARFARIN (267 patients)
DOXYCYCLINE (264 patients)
GEMZAR (263 patients)
VALIUM (263 patients)
COREG (263 patients)
IMITREX (262 patients)
LEUCOVORIN CALCIUM (261 patients)
CYCLOBENZAPRINE (261 patients)
TYLENOL (CAPLET) (254 patients)
ADRIAMYCIN PFS (254 patients)
SOLU-MEDROL (253 patients)
SORAFENIB (251 patients)
GEMCITABINE (250 patients)
OXALIPLATIN (250 patients)
CETUXIMAB (249 patients)
AUGMENTIN '125' (249 patients)
BACLOFEN (249 patients)
AMITRIPTYLINE HCL (248 patients)
ARIMIDEX (247 patients)
RANITIDINE (246 patients)
KEFLEX (245 patients)
DOXORUBICIN HCL (245 patients)
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% (244 patients)
IBUPROFEN (ADVIL) (243 patients)
DIAZEPAM (242 patients)
NYSTATIN (240 patients)
MIRALAX (235 patients)
VALTREX (232 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about DEEP VEIN THROMBOSIS and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.